Goldman Sachs Group Inc Chinook Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	BUY	$18.66 - $38.58 $2.96 Million - $6.12 Million	158,756 Added 45.45%	508,062 $19.5 Million
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $2.96 Million - $6.12 Million	158,756 Added 45.45%	508,062 $19.5 Million
Q1 2023 May 14, 2024	BUY	$21.53 - $26.8 $2.95 Million - $3.68 Million	137,130 Added 64.63%	349,306 $8.09 Million
Q1 2023 May 11, 2023	BUY	$21.53 - $26.8 $2.95 Million - $3.68 Million	137,130 Added 64.63%	349,306 $8.09 Million
Q4 2022 May 14, 2024	SELL	$18.63 - $27.35 $3.55 Million - $5.21 Million	-190,414 Reduced 47.3%	212,176 $5.56 Million
Q4 2022 Feb 13, 2023	SELL	$18.63 - $27.35 $3.55 Million - $5.21 Million	-190,414 Reduced 47.3%	212,176 $5.56 Million
Q3 2022 May 14, 2024	BUY	$17.51 - $23.37 $2.96 Million - $3.95 Million	168,861 Added 72.25%	402,590 $7.92 Million
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $2.96 Million - $3.95 Million	168,861 Added 72.25%	402,590 $7.91 Million
Q2 2022 May 14, 2024	BUY	$12.59 - $18.8 $2.94 Million - $4.39 Million	233,729 New	233,729 $4.09 Million
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $12,703 - $18,969	-1,009 Reduced 0.43%	233,729 $4.09 Million
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $198,474 - $275,585	16,512 Added 7.57%	234,738 $3.84 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $248,959 - $391,953	23,289 Added 11.95%	218,226 $3.56 Million
Q3 2021 Nov 10, 2021	BUY	$11.5 - $14.86 $2.24 Million - $2.9 Million	194,937 New	194,937 $2.49 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.